世界の希少疾患治療薬は2021年に1,471億2,000万米ドルと評価されました。研究活動や新規治療薬の開発への注目が高まっていることが、希少疾患治療薬治療薬市場の成長を促しています。さらに、製品開発の進展により、希少な遺伝性疾患の診断に技術的に優れた革新的なデバイスの導入が進んでいます。
さらに、希少疾患治療薬に関する意識向上を目的とした政府の好意的な政策により、希少疾患の効果的な治療法の採用が増加しています。しかし、希少疾患治療薬の医薬品開発には、患者数の少なさ、病態や進行の理解の不十分さ、確立されたエンドポイントの欠如など、効率的かつ効果的な臨床試験を阻害するいくつかの要因が存在します。そのため、複数の規制機関が、患者の安全性と薬剤の有効性を確保するために、希少疾患治療薬の医薬品承認に関する規制基準の実施に取り組んでいます。
さらに、希少疾患の検出の改善と診断率の向上は、コストの上昇に寄与する可能性があります。 希少疾患治療薬の人道的利益は議論の余地がありませんが、支払者がどのように医療給付を管理・運用するかに大きな影響を与え、最終的に患者のオーファンドラッグへのアクセスを左右することになります。また、生物学的製剤は、先進国での有病率が高い癌などの希少疾患の副作用の少ない治療薬として使用されています。
目次
Table of Contents
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Rare Disease Drugs Market: Product Outlook
4. Global Rare Disease Drugs Market: Sizing and Forecast
4.1 Global Rare Disease Drugs Market Size, By Value, 2017-2027
4.2 Impact of COVID-19 on Global Rare Disease Drugs Market
5. Global Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel
5.1 Competitive Scenario of Global Rare Disease Drugs Market: By Drug Type
5.1.1 Biologics - Market Size and Forecast (2017-2027)
5.1.2 Non-Biologics - Market Size and Forecast (2017-2027)
5.2 Competitive Scenario of Global Rare Disease Drugs Market: By Therapeutic Area
5.2.1 Infectious disease - Market Size and Forecast (2017-2027)
5.2.2 Oncology- Market Size and Forecast (2017-2027)
5.2.3 Neurological - Market Size and Forecast (2017-2027)
5.2.4 Metabolic - Market Size and Forecast (2017-2027)
5.2.5 Others - Market Size and Forecast (2017-2027)
5.3 Competitive Scenario of Global Rare Disease Drugs Market: By Patients
5.3.1 Paediatric - Market Size and Forecast (2017-2027)
5.3.2 Adults - Market Size and Forecast (2017-2027)
5.4 Competitive Scenario of Global Rare Disease Drugs Market: By Route of Administration
5.4.1 Oral - Market Size and Forecast (2017-2027)
5.4.2 Injectable - Market Size and Forecast (2017-2027)
5.5 Competitive Scenario of Global Rare Disease Drugs Market: By Distribution Channel
5.5.1 Hospitals & Retail Pharmacies- Market Size and Forecast (2017-2027)
5.5.2 Online Pharmacies - Market Size and Forecast (2017-2027)
6. Global Rare Disease Drugs Market: Regional Analysis
6.1 Competitive Scenario of Global Rare Disease Drugs Market: By Region
7. North America Rare Disease Drugs Market: An Analysis (2017-2027)
7.1 North America Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.2 North America Rare Disease Drugs Market - Prominent Companies
7.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)
7.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic and Others)
7.5 Market Segmentation By Patients Type (Pediatric, Adults)
7.6 Market Segmentation By Route of Administration (Oral, Injectable)
7.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
7.8 North America Rare Disease Drugs Market: Country Analysis
7.9 Market Opportunity Chart of North America Rare Disease Drugs Market - By Country, By Value, 2027
7.10 Competitive Scenario of North America Rare Disease Drugs Market: By Country
7.11 United States Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.12 United States Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
7.13 Canada Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.14 Canada Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8. Europe Rare Disease Drugs Market: An Analysis (2017-2027)
8.1 Europe Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.2 Europe Rare Disease Drugs Market - Prominent Companies
8.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)
8.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic, Others)
8.5 Market Segmentation By Patients Type (Pediatric, Adults)
8.6 Market Segmentation By Route of Administration (Oral, Injectable)
8.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
8.8 Europe Rare Disease Drugs Market: Country Analysis
8.9 Market Opportunity Chart of Europe Rare Disease Drugs Market - By Country, By Value, 2027
8.10 Competitive Scenario of Europe Rare Disease Drugs Market: By Country
8.11 Germany Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.12 Germany Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.13 United Kingdom Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.14 United Kingdom Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.15 France Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.16 France Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.17 Italy Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.18 Italy Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9. Asia Pacific Rare Disease Drugs Market: An Analysis (2017-2027)
9.1 Asia Pacific Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.2 Asia Pacific Rare Disease Drugs Market - Prominent Companies
9.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)
9.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic, Others)
9.5 Market Segmentation By Patients Type (Pediatric, Adults)
9.6 Market Segmentation By Route of Administration (Oral, Injectable)
9.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
9.8 Asia Pacific Rare Disease Drugs Market: Country Analysis
9.9 Market Opportunity Chart of Asia Pacific Rare Disease Drugs Market - By Country, By Value, 2027
9.10 Competitive Scenario of Asia Pacific Rare Disease Drugs Market: By Country
9.11 China Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.12 China Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.13 Japan Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.14 Japan Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.15 India Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.16 India Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.17 South Korea Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.18 South Korea Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
10. Global Rare Disease Drugs Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Drug Class, 2027
11.2 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Therapeutic Area, 2027
11.3 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Patients, 2027
11.4 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Route of Administration, 2027
11.5 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Distribution Channel, 2027
11.6 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Region, 2027
12. Competitive Landscape
12.1 Market Share Analysis
13. Company Analysis
13.1 Takeda Pharmaceutical Company Limited
13.2 Sanofi
13.3 Merck KGaA
13.4 F. Hoffman-La Roche Ltd.
13.5 Pfizer
13.6 Novartis AG
13.7 Bayer Group
13.8 Biogen
13.9 GlaxoSmithKline
13.10 AbbVie Inc.
List of Figures
Figure 1: Global Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 3: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 4: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 5: Prevalence of Rare Disease Drugss in the U.S., EU, and estimated prevalence in China, (In Million)2021
Figure 6: World’s leading causes of death (in millions), 2018
Figure 7: World Population 65 Years & Above (% of Total), 2015-2019
Figure 8: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 9: Global Rare Disease Drugs - Clinical Trial
Figure 10: Global Rare Disease Drugs Market- By Drug Type Market Share, 2021 & 2027
Figure 11: Global Rare Disease Drugs Market- By Biologics, By Value (USD Billion), 2017-2027
Figure 12: Global Rare Disease Drugs Market- By Non-Biologics, By Value (USD Billion), 2017-2027
Figure 13: Global Rare Disease Drugs Market- By Therapeutic Area Market Share, 2021 & 2027
Figure 14: Global Rare Disease Drugs Market- By Infectious Disease, By Value (USD Billion), 2017-2027
Figure 15: Global Rare Disease Drugs Market- By Oncology, By Value (USD Billion), 2017-2027
Figure 16: Global Rare Disease Drugs Market- By Neurological, By Value (USD Billion), 2017-2027
Figure 17: Global Rare Disease Drugs Market- By Metabolic, By Value (USD Billion), 2017-2027
Figure 18: Global Rare Disease Drugs Market- By Others, By Value (USD Billion), 2017-2027
Figure 19: Global Rare Disease Drugs Market- By patients Market Share, 2021 & 2027
Figure 20: Global Rare Disease Drugs Market- By Pediatric, By Value (USD Billion), 2017-2027
Figure 21: Global Rare Disease Drugs Market- By Adults, By Value (USD Billion), 2017-2027
Figure 22: Global Rare Disease Drugs Market- By Route of Administration Market Share, 2021 & 2027
Figure 23: Global Rare Disease Drugs Market- By Oral, By Value (USD Billion), 2017-2027
Figure 24: Global Rare Disease Drugs Market- By Injectable, By Value (USD Billion), 2017-2027
Figure 25: Global Rare Disease Drugs Market- By Distribution Channel Market Share, 2021 & 2027
Figure 26: Global Rare Disease Drugs Market- By Hospital & Retail Pharmacies, By Value (USD Billion), 2017-2027
Figure 27: Global Rare Disease Drugs Market- By Online Pharmacies, By Value (USD Billion), 2017-2027
Figure 28: Global Rare Disease Drugs Market- By Region Market Share, 2021 & 2027
Figure 29: North America Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 30: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 31: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 32: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 33: North America Population ages 65 and above (% of total Population), 2016-2020
Figure 34: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 35: North America Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 36: North America Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 37: North America Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 38: North America Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 39: North America Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 40: Market Opportunity Chart of North America Rare Disease Drugs Market- By Country, By Value (Year-2027)
Figure 41: North America Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
Figure 42: United States Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 43: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 44: United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 45: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 46: United States Population aged 65 and above (% of total Population), 2016-2020
Figure 47: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 48: United State National Institute of Health Spending on Rare Disease Drugs, ( USD Million), 2016-2020
Figure 49: Median U.S. cost per patient per year for top 100 products, 2015-2018
Figure 50: United States Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 51: United States Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 52: United States Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 53: United States Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 54: United States Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 55: Canada Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 56: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 57: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 58: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 59: Canada Population aged 65 and above (% of total Population), 2016-2020
Figure 60: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 61: Canada Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 62: Canada Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 63: Canada Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 64: Canada Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 65: Canada Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 66: Europe Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 67: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 68: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 69: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 70: European Countries Population ages 65 and above (% of total Population), 2020
Figure 71: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 72: Europe Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 73: Europe Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 74: Europe Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 75: Europe Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 76: Europe Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 77: Market Opportunity Chart of Europe Rare Disease Drugs Market- By Country, By Value (Year -2027)
Figure 78: Europe Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
Figure 79: Germany Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 80: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 81: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 82: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 83: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 84: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 85: Germany Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 86: Germany Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 87: Germany Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 88: Germany Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 89: Germany Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 90: United Kingdom Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 91: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 92: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 93: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 94: United Kingdom Population ages 65 and above (% of total Population), 2016-20
Figure 95: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 96: United Kingdom Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 97: United Kingdom Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 98: United Kingdom Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 99: United Kingdom Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 100: United Kingdom Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 101: France Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 102: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 103: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 104: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 105: France Population ages 65 and above (% of total Population), 2016-20
Figure 106: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 107: France Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 108: France Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 109: France Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 110: France Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 111: France Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 112: Italy Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 113: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 114: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 115: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 116: Italy Population ages 65 and above (% of total Population), 2016-20
Figure 117: Italy Trend of expenditure for orphan drugs in Italy from 2016 to 2020 (In Euro USD)
Figure 118: Italy Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 119: Italy Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 120: Italy Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 121: Italy Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 122: Italy Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 123: Asia Pacific Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 124: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 125: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 126: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 127: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Figure 128: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 129: Asia Pacific Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 130: Asia Pacific Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 131: Asia Pacific Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 132: Asia Pacific Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 133: Asia Pacific Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 134: Market Opportunity Chart of APAC Rare Disease Drugs Market- By Country, By Value (Year -2027)
Figure 135: APAC Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
Figure 136: China Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 137: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 138: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 139: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 140: China Population ages 65 and above, by Countries (% of total Population), 2020
Figure 141: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 142: China Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 143: China Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 144: China Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 145: China Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 146: China Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 147: Japan Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 148: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 149: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 150: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 151: Japan Population ages 65 and above (% of total Population), 2016-20
Figure 152: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 153: Japan Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 154: Japan Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 155: Japan Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 156: Japan Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 157: Japan Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 158: India Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 159: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 160: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 161: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 162: India Population ages 65 and above (% of total Population), 2016-20
Figure 163: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 164: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 165: e-pharmacy market in India (USD Million)
Figure 166: India Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 167: India Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 168: India Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 169: India Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 170: India Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 171: South Korea Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 172: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 173: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 174: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 175: South Korea Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 176: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 177: South Korea Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 178: South Korea Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 179: South Korea Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 180: South Korea Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 181: South Korea Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 182: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Drug Type (Year -2027)
Figure 183: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Therapeutic Area (Year-2027)
Figure 184: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Patients(Year -2027)
Figure 185: Market Attractiveness Chart of Global Rare Disease Drugs Market- By route of Administration (Year -2027)
Figure 186: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Distribution Channel (Year-2027)
Figure 187: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Region (Year -2027)
Figure 188: Global Rare Disease Drugs company market share (%), 2020
Figure 189: Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Figure 190: Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Figure 191: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Figure 192: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
Figure 193: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 194: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 195: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 196: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 197: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 198: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 199: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 200: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 201: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 202: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 203: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 204: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 205: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 206: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 207: Pfizer sales Revenue, By Geographical Segment (%), FY2020
Figure 208: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 209: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 200: Novartis Sales Revenue Split, By Business Segment (USD Billion), FY2020
Figure 211: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 212: Bayer Group Sales Revenues, 2016-2020 (USD Million)
Figure 213: Bayer Group Net Profit, 2016-2020 (USD Million)
Figure 214: Bayer Group, By Business Segment (%), FY2020
Figure 215: Bayer Group, By Geographical Segment (%), FY2020
Figure 216: Biogen Sales Revenues, 2016-2020 (USD Million)
Figure 217: Biogen Net Profit, 2016-2020 (USD Million)
Figure 218: Biogen, By Business Segment (%), FY2020
Figure 219: Biogen, By Geographical Segment (%), FY2020
Figure 220: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 221: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 222: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 223: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 224: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Figure 225: AbbVie Inc. Net Income (USD Million), 2016-2020
Figure 226: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 227: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
